ASH 2022 | An update on the use of navtemadlin in myelofibrosis
Srdan Verstovsek, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares the latest updates on studies evaluating navtemadlin in myelofibrosis (MF), highlighting the Phase III BOREAS trial (NCT03662126) comparing this agent with best available therapy (BAT) in R/R patients, and a Phase II study evaluating navtemadlin in combination with ruxolitinib (NCT04485260). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
NS Pharma: Research Funding; AstraZeneca: Research Funding; ItalPharma: Research Funding; Novartis: Consultancy, Research Funding; Incyte: Consultancy, Research Funding; Promedior: Research Funding; CTI BioPharma Corp.: Research Funding; Gilead: Research Funding; Sierra Oncology: Consultancy, Research Funding; Roche: Research Funding; Protagonist Therapeutics: Research Funding; PharmaEssentia: Research Funding; Blueprints Medicines Corp.: Research Funding; Celgene: Consultancy, Research Funding; Genentech: Research Funding; Pragmatist: Consultancy; Constellation Pharmaceuticals: Consultancy.
